Playtech plc (LON:PTEC – Get Free Report) insider Chris McGinnis acquired 27,080 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of GBX 372 per share, for a total transaction of £100,737.60.
Playtech Stock Up 0.5%
PTEC stock traded up GBX 1.80 during trading on Wednesday, reaching GBX 365. The stock had a trading volume of 71,807,813 shares, compared to its average volume of 12,699,473. The firm has a fifty day moving average price of GBX 367.84 and a 200 day moving average price of GBX 315.52. The company has a market capitalization of £1.01 billion, a P/E ratio of 0.75, a PEG ratio of 1.28 and a beta of 0.65. Playtech plc has a 1-year low of GBX 210 and a 1-year high of GBX 447. The company has a current ratio of 1.42, a quick ratio of 1.09 and a debt-to-equity ratio of 24.36.
Playtech announced that its Board of Directors has authorized a share repurchase plan on Friday, March 27th that allows the company to buyback 5,660,000 shares. This buyback authorization allows the company to buy shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its shares are undervalued.
Analysts Set New Price Targets
View Our Latest Stock Analysis on PTEC
About Playtech
Playtech plc, a technology company, provides gambling software, services, content, and platform technologies worldwide. The company offers technologies across various product verticals, including live casino, sports, bingo, virtual sports, and poker. It also owns the intellectual property rights and licenses the software; provides digital marketing and advertising, consulting and online technical support, data mining processing, turnkey, live game, and video stream services; and operates betting shops.
See Also
- Five stocks we like better than Playtech
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
- The Great AI Rotation: Cashing In on Data
- Mirum Pharma: A Rare Disease Growth Story to Watch
Receive News & Ratings for Playtech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Playtech and related companies with MarketBeat.com's FREE daily email newsletter.
